prothrombin

Summary

Summary: A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.

Top Publications

  1. ncbi Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: localization, expression and participation in neurodegenerative diseases
    Elena Sokolova
    Otto von Guericke Universitaet Magdeburg, Medizinische Fakultat, Institut fur Neurobiochemie, Leipziger Strasse 44, Magdeburg, Germany
    Thromb Haemost 100:576-81. 2008
  2. ncbi Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single nucleotide polymorphisms among Arabs
    Wassim Y Almawi
    Al Jawhara Center for Molecular Medicine, Genetics and Inherited Diseases, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain
    J Thromb Thrombolysis 20:163-8. 2005
  3. ncbi High incidence of factor V Leiden and prothrombin G20210A in healthy southern Italians
    Gianluca Sottilotta
    Centro Emofilia, Servizio Emostasi e Trombosi, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Clin Appl Thromb Hemost 15:356-9. 2009
  4. ncbi Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism
    D Coen
    Clinical Institute of Laboratory Diagnostics, Zagreb University Hospital Center, Zagreb, Croatia
    Croat Med J 42:488-92. 2001
  5. ncbi Thrombogenicity of prothrombin complex concentrates
    M Kohler
    Department of Transfusion Medicine, University of Gottingen, Germany
    Thromb Res 95:S13-7. 1999
  6. ncbi Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution
    Elisabeth Mazoyer
    Hématologie biologique, Hopital Lariboisiere, Paris, France
    Blood Coagul Fibrinolysis 20:503-10. 2009
  7. ncbi Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal
    Ingrid Pabinger
    Department of Internal Medicine, Division of Haematology and Haemostaseology, Medical University Vienna, Vienna, Austria
    Ann Hematol 89:309-16. 2010
  8. ncbi Absence of factor V Leiden mutation and low prothrombin G 20210 A mutation prevalence in a healthy Moroccan population
    Florence Mathonnet
    Thromb Haemost 88:1073-4. 2002
  9. ncbi Prevalence of factor V Leiden, prothrombin and methylene tetrahydrofolate reductase mutations in women with adverse pregnancy outcomes in Lebanon
    Laila F Zahed
    Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Lebanon
    Am J Obstet Gynecol 195:1114-8. 2006
  10. ncbi Prevalence of antiphospholipid antibodies, factor V G1691A (Leiden) and prothrombin G20210A mutations in early and late recurrent pregnancy loss
    Nabil Mtiraoui
    Research Unit of Haematological and Autoimmune Diseases, Faculty of Pharmacy, Monastir, Center University, Tunisia
    Eur J Obstet Gynecol Reprod Biol 119:164-70. 2005

Research Grants

  1. Dual Direct Inhibitors of Thrombin and Factor Xa
    Umesh Desai; Fiscal Year: 2009
  2. Dual Direct Inhibitors of Thrombin and Factor Xa
    UMESH RAMANLAL DESAI; Fiscal Year: 2010
  3. Physiology and Molecular Biology of Factor XI
    David Gailani; Fiscal Year: 2009
  4. Physiology and Molecular Biology of Factor XI
    David Gailani; Fiscal Year: 2010
  5. Improved liver function and regeneration with A20
    Christiane Ferran; Fiscal Year: 2003
  6. Improved liver function and regeneration with A20
    Christiane Ferran; Fiscal Year: 2006
  7. Lipid Regulation of Thrombin Generation
    Barry R Lentz; Fiscal Year: 2010
  8. METAL DEPENDENT COMPLEXES IN BLOOD COAGULATION
    Barbara Furie; Fiscal Year: 2002
  9. ANTIBODIES WITH PROTHROMBINASE ACTIVITY IN LUPUS
    Perumal Thiagarajan; Fiscal Year: 2003
  10. Lipid Regulation of Thrombin Generation
    Barry R Lentz; Fiscal Year: 2010

Detail Information

Publications225 found, 100 shown here

  1. ncbi Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: localization, expression and participation in neurodegenerative diseases
    Elena Sokolova
    Otto von Guericke Universitaet Magdeburg, Medizinische Fakultat, Institut fur Neurobiochemie, Leipziger Strasse 44, Magdeburg, Germany
    Thromb Haemost 100:576-81. 2008
    ..Both prothrombin and its active form thrombin have been detected locally in the brain...
  2. ncbi Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single nucleotide polymorphisms among Arabs
    Wassim Y Almawi
    Al Jawhara Center for Molecular Medicine, Genetics and Inherited Diseases, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain
    J Thromb Thrombolysis 20:163-8. 2005
    Factor V G1691A (FV-Leiden) and prothrombin (PRT) G20210A single nucleotide polymorphisms (SNPs) are major inherited risk factors of venous thromboembolism...
  3. ncbi High incidence of factor V Leiden and prothrombin G20210A in healthy southern Italians
    Gianluca Sottilotta
    Centro Emofilia, Servizio Emostasi e Trombosi, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Clin Appl Thromb Hemost 15:356-9. 2009
    Factor V Leiden (FVL) and G20210 prothrombin (FII G20210A) mutations are risk factors for thromboembolism...
  4. ncbi Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism
    D Coen
    Clinical Institute of Laboratory Diagnostics, Zagreb University Hospital Center, Zagreb, Croatia
    Croat Med J 42:488-92. 2001
    To determine the prevalences of factor V Leiden and the G20210A mutation in the prothrombin gene (PT20210A) and the frequency of their association in healthy subjects and in patients with venous thromboembolism (VTE).
  5. ncbi Thrombogenicity of prothrombin complex concentrates
    M Kohler
    Department of Transfusion Medicine, University of Gottingen, Germany
    Thromb Res 95:S13-7. 1999
    Thrombogenicity of factor IX complex or prothrombin complex concentrates (PCC) is a well-acknowledged problem...
  6. ncbi Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution
    Elisabeth Mazoyer
    Hématologie biologique, Hopital Lariboisiere, Paris, France
    Blood Coagul Fibrinolysis 20:503-10. 2009
    ..Thirty percent of variation in plasma prothrombin level was explained by environmental factors (serum cholesterol, age, oral contraception, hormonal replacement ..
  7. ncbi Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal
    Ingrid Pabinger
    Department of Internal Medicine, Division of Haematology and Haemostaseology, Medical University Vienna, Vienna, Austria
    Ann Hematol 89:309-16. 2010
    b>Prothrombin complex concentrate (PCC) infusion is preferred for emergency reversal of coumarin therapy...
  8. ncbi Absence of factor V Leiden mutation and low prothrombin G 20210 A mutation prevalence in a healthy Moroccan population
    Florence Mathonnet
    Thromb Haemost 88:1073-4. 2002
  9. ncbi Prevalence of factor V Leiden, prothrombin and methylene tetrahydrofolate reductase mutations in women with adverse pregnancy outcomes in Lebanon
    Laila F Zahed
    Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Lebanon
    Am J Obstet Gynecol 195:1114-8. 2006
    The purpose of this study was to determine the prevalence of factor V Leiden, prothrombin, and methylene tetrahydrofolate reductase gene mutations in women with adverse pregnancy outcome compared with women who had uneventful pregnancies.
  10. ncbi Prevalence of antiphospholipid antibodies, factor V G1691A (Leiden) and prothrombin G20210A mutations in early and late recurrent pregnancy loss
    Nabil Mtiraoui
    Research Unit of Haematological and Autoimmune Diseases, Faculty of Pharmacy, Monastir, Center University, Tunisia
    Eur J Obstet Gynecol Reprod Biol 119:164-70. 2005
    ..We assessed the prevalence of inherited (FV-Leiden and PRT G20210A), and acquired (anti-PL antibodies) risk factors among habitual aborters in Tunisia...
  11. ncbi Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate
    Herbert Schöchl
    Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Dr Franz Rehrl Platz 5, Salzburg, Austria
    Crit Care 14:R55. 2010
    ..The appropriate strategy for trauma-induced coagulopathy management is under debate. We report the treatment of major trauma using mainly coagulation factor concentrates...
  12. ncbi Factor V Leiden and prothrombin gene G20210A mutations are uncommon in portal vein thrombosis in India
    Sanjay Sharma
    Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226 014, India
    Indian J Gastroenterol 25:236-9. 2006
    ..The cause of thrombosis in these patients remains unclear. We studied the frequency of mutations in genes for coagulation factors V and II (prothrombin) in 61 Indian patients with PVT and 49 healthy control subjects.
  13. ncbi Factor V Leiden G1691A and prothrombin G20210A mutations are common in Tunisia
    C Frere
    J Thromb Haemost 1:2451-2. 2003
  14. ncbi Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in 200 healthy Jordanians
    Suhair S Eid
    Molecular Laboratory, King Hussein Medical Centre, Jordan
    Clin Lab Sci 17:200-2. 2004
    ..In order to estimate the frequency of the factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in the Jordanian population, we screened 200 healthy Jordanian individuals...
  15. ncbi Prevalence of two thrombophilia predisposing mutations: factor V G1691A (R506Q; Leiden) and prothrombin G20210A, among healthy Lebanese
    Hala Tamim
    Thromb Haemost 88:691-2. 2002
  16. ncbi Prevalence of angiotensin-converting enzyme, methylenetetrahydrofolate reductase, Factor V Leiden, prothrombin and apolipoprotein E gene polymorphisms in Morocco
    Thierry Paluku They-They
    Laboratoire de Génétique Médicale et Pathologie Moléculaire LGPM, Faculté de Médecine et de Pharmacie Casablanca, 19 rue Tarik Ibn Ziad, Casablanca, Morocco
    Ann Hum Biol 37:767-77. 2010
    ..These genetic factors are involved in several pathways affecting blood pressure regulation, blood coagulation, homocysteine and lipid metabolisms...
  17. ncbi Exosite-driven substrate specificity and function in coagulation
    S Krishnaswamy
    Joseph Stokes Research Institute, Children s Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Thromb Haemost 3:54-67. 2005
    ..Exosite-driven enzymic function probably represents a widely employed biological strategy for the achievement of high macromolecular substrate specificity...
  18. ncbi Distinct association of factor V-Leiden and prothrombin G20210A mutations with deep venous thrombosis in Tunisia and Lebanon
    Lobna Bouaziz-Borgi
    Faculty of Pharmacy, University of Monastir, Tunisia
    Am J Hematol 81:641-3. 2006
    Factor V G1691A (FV-Leiden) and prothrombin (PRT) G20210A single nucleotide polymorphisms (SNPs) were associated with venous thrombosis among Caucasians...
  19. ncbi Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review
    Jodi B Segal
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    JAMA 301:2472-85. 2009
    ..Testing for genetic risks for venous thromboembolism (VTE) is common, but the safety and utility of such testing need review...
  20. ncbi Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate
    Ingrid Pabinger-Fasching
    Haematology and Haemostaseology Division, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
    Thromb Res 122:S19-22. 2008
    Bleeding can be a major problem in patients on oral anticoagulation therapy. Beriplex P/N is a prothrombin complex concentrate (PCC) that has been developed for the rapid reversal of anticoagulation in patients requiring immediate ..
  21. ncbi Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale
    Vesa Karttunen
    Department of Neurology, Oulu University Central Hospital, Box 25, FIN 90029 Oulu, Finland
    Blood Coagul Fibrinolysis 14:261-8. 2003
    ..We assessed the occurrence of several prothrombotic states (factor V Leiden, prothrombin G20210A, deficiencies in protein S, protein C and antithrombin, lupus anticoagulant, anticardiolipin antibodies,..
  22. ncbi High frequency of factor V Leiden and prothrombin G20210A mutations in Greek hemophiliacs
    Z J Foka
    J Thromb Haemost 1:1116-7. 2003
  23. ncbi Clinical manifestations of the prothrombin G20210A mutation in children: a pediatric coagulation consortium study
    G Young
    Children s Hospital of Orange County, Orange, California 92868, USA
    J Thromb Haemost 1:958-62. 2003
    The prothrombin G20210A mutation is a common risk factor for thrombosis which increases the risk of deep vein thrombosis, stroke, and fetal loss. There are few publications of its clinical manifestations in children...
  24. ncbi Factor V Leiden and prothrombin gene 20210A variant in neonatal thromboembolism and in healthy neonates and adults: a study in a single center
    Begum Atasay
    Division of Neonatology, Department of Pediatrics, Ankara University School of Medicine, Ankara, Turkey
    Pediatr Hematol Oncol 20:627-34. 2003
    ..Investigations included screening for factor V 1691A and prothrombin 20210A. Seven of 9 neonates had one or more risk factors at the time of thromboembolism...
  25. ncbi Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR G677A among 594 thrombotic Jordanian patients
    Suhair S Eid
    King Hussein Medical Center, Princess Iman Research Center for Laboratory Sciences, Amman, Jordan
    Blood Coagul Fibrinolysis 16:417-21. 2005
    ..In order to estimate the frequency of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in Jordanian thrombotic patients, we studied 594 patients admitted to the ..
  26. ncbi The prevalence of factor V Leiden (G1691A), prothrombin G20210A and methylenetetrahydrofolate reductase C677T mutations in Jordanian patients with beta-thalassemia major
    Suleimman A Al-Sweedan
    Department of Pediatrics, Jordan University of Science and Technology, Irbid, Jordan
    Blood Coagul Fibrinolysis 20:675-8. 2009
    ..Factor V Leiden and prothrombin G20210A and methylenetetrahydrofolate reductase (MTHFR) gene mutations were genotyped by PCR and allele-..
  27. ncbi Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome
    T Agorastos
    First University Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Greece
    J Matern Fetal Neonatal Med 12:267-73. 2002
    ..The aim of this study was to investigate the relationship between specific obstetric adverse outcomes and factor V Leiden and prothrombin G20210A mutations.
  28. ncbi The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey
    Sibel Kabukcu
    Pamukkale University Faculty of Medicine, Denizli, Turkey
    Clin Appl Thromb Hemost 13:166-71. 2007
    ..of FV Leiden and coinheritance of FV Leiden with two other frequent hereditary thrombophilia causes, namely, prothrombin G20210A and methylene-tetrahydrofolate reductase (MTHFR) C677T mutation in the Aegean region of Turkey...
  29. ncbi Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation
    Akinobu Taketomi
    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Transplantation 87:531-7. 2009
    ....
  30. ncbi Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway
    Pan Yue
    Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, Jinan, China
    Eur J Cancer 47:1115-24. 2011
    Des-γ-carboxy prothrombin (DCP), an aberrant prothrombin produced by hepatocellular carcinoma (HCC) cells, has been shown to be associated with the biological malignant potential of HCC...
  31. ncbi The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both
    I Martinelli
    Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, University of Milan, Italy
    Br J Haematol 111:1223-9. 2000
    Factor V Leiden and the G20210A mutation in the prothrombin gene are the most frequent abnormalities associated with venous thromboembolism. It is unknown whether the risks due to the presence of either mutation are of the same magnitude...
  32. ncbi Prevalence of factor V Leiden and prothrombin G20210A gene mutation
    Ahmet Irdem
    Department of Pediatrics, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
    Saudi Med J 26:580-3. 2005
    To determine the prevalence of factor V Leiden (FVL) and prothrombin gene (PG) 20210A mutations in patients who attended the outpatient clinic and do not have a family history of thrombosis.
  33. ncbi Haplotypes of the EPCR gene, prothrombin levels, and the risk of venous thrombosis in carriers of the prothrombin G20210A mutation
    Silvia Navarro
    Research Center, La Fe University Hospital, Valencia, Spain
    Haematologica 93:885-91. 2008
    ..We assessed whether these haplotypes modify the risk of venous thromboembolism in carriers of the prothrombin 20210A allele.
  34. ncbi The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin
    Ken Shirabe
    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    J Surg Oncol 95:235-40. 2007
    ..The size and histological grade of the tumor were significantly correlated with the mvi. The des-gamma-carboxy prothrombin (DCP) is a mvi predictor...
  35. ncbi The O blood group protects against venous thromboembolism in individuals with the factor V Leiden but not the prothrombin (factor II G20210A) mutation
    A J González Ordóñez
    Hematology Department, Hospital S Agustín, Aviles, Spain
    Blood Coagul Fibrinolysis 10:303-7. 1999
    ..30+/-0.51 U/ ml; P < 0.0001). We speculate that factor Va in individuals with the factor V Leiden mutation could interact with the high levels of factor VIII clotting activity as a necessary cofactor...
  36. ncbi The omega-loop region of the human prothrombin gamma-carboxyglutamic acid domain penetrates anionic phospholipid membranes
    L A Falls
    Division of Hemostasis and Thrombosis Research, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Biol Chem 276:23895-902. 2001
    The hydrophobic omega-loop within the prothrombin gamma-carboxyglutamic acid-rich (Gla) domain is important in membrane binding...
  37. ncbi The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia
    A Gerhardt
    Department of Obstetrics and Gynecology, Heinrich Heine University Medical Center, Dusseldorf, Germany
    J Thromb Haemost 3:686-91. 2005
    ..9, 95% confidence interval (CI) 0.4, 2.2; prothrombin mutation, OR 1.9, 95% CI 0.5, 7.0; methylentetrahydrofolate reductase 677TT genotype, OR 0.8, 95% CI 0.4, 1...
  38. ncbi G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3'-end formation
    H Ceelie
    Hemostasis and Thrombosis Research Center, Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
    J Thromb Haemost 2:119-27. 2004
    The prothrombin G20210A mutation is associated with increased plasma prothrombin levels and risk of thrombosis...
  39. ncbi A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma
    G Bertino
    Department of Internal Medicine and Systemic Diseases, Santa Marta Hospital, University of Catania, Catania, Italy
    Panminerva Med 50:221-6. 2008
    Des-gamma-carboxy prothrombin (DCP) is an abnormal prothrombin, increased in serum of patients with hepatocellular carcinoma (HCC) as result of an acquired defect of post-translational carboxylation of prothrombin's precursor...
  40. ncbi Factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T are not associated with coronary artery disease and type 2 diabetes mellitus in western Iran
    Zohreh Rahimi
    Medical Biology Research Center, Kermanshah University of Medical Sciences, Medical School, Kermanshah, Iran
    Blood Coagul Fibrinolysis 20:252-6. 2009
    There are controversial results related to the contribution of factor V Leiden G1691A, prothrombin gene G20210A and methylentetrahydrofolate reductase (MTHFR) C677T mutations in the development of coronary artery disease (CAD) and their ..
  41. ncbi A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation
    Michiel Coppens
    Department of Vascular Medicine F4 276, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Blood 108:2604-7. 2006
    The prothrombin 20210A mutation has been associated with an increased risk for venous thromboembolism (VTE) and arterial cardiovascular disease...
  42. ncbi Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke
    Justo Aznar
    La Fe University Hospital, Department of Clinical Pathology, Avd Campanar 21, 46009 Valencia, Spain
    Thromb Haemost 91:1031-4. 2004
    The association between factor V Leiden (FVL) and prothrombin G20210A (PT 20210) mutations and ischemic stroke remains controversial, particularly in young adults with cryptogenic stroke. Prevalence of FVL (4.1%) and PT 20210 (8...
  43. ncbi Prothrombin G20210A is not prevalent in North India
    G Garewal
    J Thromb Haemost 1:2253-4. 2003
  44. ncbi [Prevalence of G20210A prothrombin gene mutation in Poland]
    K Bykowska
    Samodzielna Pracownia Krzepniecia Krwi i Hemostazy Instytutu Hematologii i Transfuzjologii w Warszawie
    Pol Arch Med Wewn 104:729-33. 2000
    The G20210A mutation of the prothrombin (PT) gene has recently been identified as a risk factor for venous thromboembolism (VTE)...
  45. ncbi Association of corticosteroids and factor V, prothrombin, and MTHFR gene mutations with avascular osteonecrosis in renal allograft recipients
    A Celik
    Division of Nephrology, Dokuz Eylul University Medical School, Izmir, Turkey
    Transplant Proc 38:512-6. 2006
    ..We investigated the associations of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations as well as cumulative corticosteroid doses with AVN in renal allograft ..
  46. ncbi High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss
    M J Kupferminc
    Department of Obstetrics and Gynecology, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, Israel
    Acta Obstet Gynecol Scand 79:963-7. 2000
    ..Our objective was to investigate the association between pregnancy complications and the guanine 20210 adenine (G20210A) mutation in prothrombin gene.
  47. ncbi Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study
    Ivan Bank
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Arch Intern Med 164:1932-7. 2004
    The prothrombin 20210A mutation has been associated with an increased risk of venous thromboembolism (VTE). Its relationship with arterial disease and pregnancy-related complications is, however, still uncertain...
  48. ncbi Purpura fulminans in a child with combined heterozygous prothrombin G20210A and factor V Leiden mutations
    N Ozbek
    Department of Pediatrics, Baskent University Faculty of Medicine, 6 Cadde No 72 3, 06490 Bahcelievler, Ankara, Turkey
    Ann Hematol 82:118-20. 2003
    ..Activated protein C resistance and prothrombin 20210 A mutation are results of point mutations described in the last decade...
  49. ncbi The use of prothrombin(S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation
    N Brufatto
    Department of Biochemistry, Queen's University, Kingston, Ontario K7L 3N6, Canada
    J Biol Chem 276:17663-71. 2001
    Serine 525 of human prothrombin was mutated to cysteine and covalently labeled with fluorescein to make II(S525C)-fluorescein. Kinetics of cleavage of this derivative by prothrombinase are identical to those of wild-type prothrombin...
  50. ncbi Heterozygous prothrombin 20210G/A mutation, associated with hyperhomocysteinemia, and homozygous methylenetetrahydrofolate reductase 677C/T mutation, in a patient with portal and mesenteric venous thrombosis
    Ihab I Elhajj
    Department of Internal Medicine, American University of Beirut Medical Center (AUBMC, Beirut, Lebanon
    Hematol J 5:540-2. 2004
    ....
  51. ncbi Prothrombin, albumin and immunoglobulin A form covalent complexes with alpha1-microglobulin in human plasma
    T Berggard
    The Section for Molecular Signalling, Department of Cell and Molecular Biology, Lund University, Sweden
    Eur J Biochem 245:676-83. 1997
    ..The other three bands were identified as prothrombin alpha1-microglobulin, albumin x alpha1-microglobulin and dimeric alpha1-microglobulin...
  52. ncbi The Ca2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1
    M Soriano-Garcia
    Department of Chemistry, Michigan State University, East Lansing 48824
    Biochemistry 31:2554-66. 1992
    The structure of Ca-prothrombin fragment 1 (residues 1-156 prothrombin) has been solved and refined at 2.2-A resolution by X-ray crystallographic methods...
  53. ncbi An Arab selective gradient in the distribution of factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T
    G Ameen
    J Thromb Haemost 3:2126-7. 2005
  54. ncbi Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain
    Tetsuaki Arai
    Department of Psychiatry, Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, BC, Canada
    J Neuropathol Exp Neurol 65:19-25. 2006
    ABSTRACT: Thrombin is a serine protease that is generated by proteolytic cleavage of its precursor, prothrombin. We previously showed that thrombin proteolyses the microtubule-associated protein tau and that phosphorylation of tau ..
  55. ncbi Association of factor V Leiden and prothrombin gene mutation with Behçet's disease
    U Tursen
    Department of Dermatology, Faculty of Medicine, Mersin University, Turkey
    Arch Dermatol Res 293:537-9. 2001
  56. ncbi Prothrombin fragment 1+2 in urine as an indicator of sustained coagulation activation after total hip arthroplasty
    Lars C Borris
    Department of Orthopaedics, Section of Traumatology, Arhus University Hospital, Arhus
    Thromb Res 121:369-76. 2007
    b>Prothrombin fragment 1+2 measured in spot urine (uF1+2) is an indicator of thrombin generation...
  57. ncbi Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke
    W Zenz
    Department of Pediatrics, University of Graz, Austria
    Thromb Haemost 80:763-6. 1998
    To investigate if the factor V Leiden mutation (F-V-LM) and/or the prothrombin gene G 20210 A variant (P-G20210A-V) are risk factors for acute stroke in Austrian children.
  58. ncbi The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism
    I Kivilcim Oguzulgen
    Department of Pulmonary Medicine, Gazi University School of Medicine, Ankara, Turkey
    Clin Appl Thromb Hemost 15:73-7. 2009
    ..association of plasminogen activator inhibitor-1 gene polymorphism and its coexistence with factor-V-Leiden and prothrombin-20210 mutations in pulmonary thromboembolism...
  59. ncbi Prothrombin index decrease: a useful and reliable marker of extensive fibrosis?
    Jean Francois Cadranel
    Unité d Hépatologie, Hopital Laennec, BP 72, 60109 Creil Cedex, France
    Eur J Gastroenterol Hepatol 14:1057-9. 2002
    ..Among those serum markers, we focused on prothrombin index, which seems to be a reliable and non-expansive marker for the diagnosis of extensive fibrosis.
  60. ncbi Prothrombin kringle-2-induced oxidative stress contributes to the death of cortical neurons in vivo and in vitro: role of microglial NADPH oxidase
    So Y Won
    Brain Disease Research Center, Ajou University School of Medicine, Suwon 443 479, South Korea
    J Neuroimmunol 214:83-92. 2009
    In the present study, we examine whether prothrombin kringle-2 (pKr-2), a domain of prothrombin distinct from thrombin and a potent microglial activator induces reactive oxygen species (ROS) generation through stimulation of microglial ..
  61. ncbi Thrombosis in children with cardiac pathology: frequency of factor V Leiden and prothrombin G20210A mutations
    A Gurgey
    Department of Pediatrics, Pediatric Hematology Unit, Hacettepe University, Faculty of Medicine, Ihsan Dogramac? Children's Hospital, 06100, Ankara, Turkey
    Pediatr Cardiol 24:244-8. 2003
    ..Two common mutations, namely factor V Leiden and prothrombin G20210A mutations, were found in 6 patients (22%)...
  62. ncbi Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee
    Anders Bjorkman
    Department of Orthopaedics, University Hospital Malmo, 20502, Malmo, Sweden
    Arch Orthop Trauma Surg 125:51-5. 2005
    ..The purpose of this study was to examine the association between osteonecrosis of the knee and abnormalities in the thrombotic pathway in the form of factor V Leiden and the prothrombin 20210A gene mutation.
  63. ncbi Role of thrombophilia in deciding on the duration of anticoagulation
    Kenneth A Bauer
    Veterans Administration Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02132, USA
    Semin Thromb Hemost 30:633-7. 2004
    ..Discovery of the factor V Leiden and prothrombin G20210A mutations has greatly increased the percentage of patients in whom venous thrombosis can be attributed ..
  64. ncbi Impact of thrombophilic genetic factors on pulmonary embolism: early onset and recurrent incidences
    Petar Ivanov
    Department of Biochemistry, University of Medicine, 1, St Kliment Ohridski Str, Pleven, 5800, Bulgaria
    Lung 186:27-36. 2008
    ..Factor V Leiden (FVL), prothrombin gene mutation G20210A (FII G20210), genetic variant C677T of the methylentetrahydrofolate reductase (MTHFR), as ..
  65. ncbi Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities
    Ida Martinelli
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Dermatology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Maggiore Policlinico, University of Milano, Italy
    Circulation 110:566-70. 2004
    ..Risk factors for primary upper-extremity DVT are not well established, and the recurrence rate is unknown...
  66. ncbi Coexistence of thrombophilic gene polymorphisms among 559 unrelated consecutive patients with a history of thrombosis
    P Madonna
    Thromb Res 101:317-9. 2001
  67. ncbi AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms
    Antonia Minano
    Centro Regional de Hemodonacion, C Ronda de Garay s n, Murcia 30003 Spain
    Haematologica 93:729-34. 2008
    Routine analyses for thrombophilia include determination of the presence of factor V Leiden and prothrombin 20210A polymorphisms...
  68. ncbi Utility of thrombin-generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency
    Nathalie Hezard
    Laboratoire d Hematologie, Centre Hospitalaire et Régional, CHU, Robert Debré, Reims, France
    Clin Chem 52:665-70. 2006
    ..The aim of this study was to evaluate the use of this assay in screening and identifying patients who require specific thrombophilic testing...
  69. ncbi Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study
    Olivia Wu
    Department of Obstetrics and Gynaecology, University of Glasgow, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, UK
    Thromb Haemost 94:17-25. 2005
    ..39 to 17.10), elevated levels of factor VIIIc (OR 8.80; 95%CI 4.13 to 18.75); and factor V Leiden and prothrombin G20210A (OR 7.85; 95%CI 1.65 to 37.41)...
  70. ncbi Screening for thrombophilia: a laboratory perspective
    Ian Jennings
    UK NEQAS Blood Coagulation, Rutledge Mews, 3 Southbourne Road, Sheffield, UK
    Br J Biomed Sci 60:39-51. 2003
    ..a modified activated protein C resistance test (with factor V-deficient plasma); polymerase chain reaction for prothrombin G20201A, together with prothrombin time, activated partial thromboplastin time, thrombin clotting time and ..
  71. ncbi Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium
    Andrea Gerhardt
    Department of Hemostasis and Tansfusion Medicine, Heinrich Heine University Medical Center, Dusseldorf, Germany
    Thromb Haemost 90:77-85. 2003
    ..005) and among carriers of combined heterozygous factor V Leiden and heterozygous G20210A mutation in the prothrombin gene 1 in 20 (odds ratio 88, p<0.001)...
  72. ncbi Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1+2, D-dimer and FVIII:C
    Edwin ten Boekel
    Laboratory for Clinical Chemistry, Hematology and Immunology, Medical Center of Alkmaar, Alkmaar, The Netherlands
    Pathophysiol Haemost Thromb 32:137-42. 2002
    ..In addition, the presence of the thrombotic risk factors G1691A-factor V, G20210A-prothrombin gene mutation and factor VIII coagulant activity (FVIII:C) was determined...
  73. ncbi The use of coagulation activation markers (soluble fibrin polymer, TpP, prothrombin fragment 1.2, thrombin-antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders
    Y S Arkel
    Maternal and Fetal Medicine Division, Department of Ob Gyn, NYU Medical Center, New York, New York 10016, USA
    Blood Coagul Fibrinolysis 13:199-205. 2002
    ..were utilized to assess these patients [enzyme-linked immunosorbent assays for soluble fibrin polymer (TpP), prothrombin fragment 1.2, thrombin-antithrombin complex, and D-dimer]...
  74. ncbi The etiologic distribution of thrombophilic factors in chronic portal vein thrombosis
    Ozgur Harmanci
    Department of Gastroenterology, Hacettepe University Faculty of Medicine, 06100 Sihhiye, Ankara, Turkey
    J Clin Gastroenterol 41:521-7. 2007
    ..We aimed to prospectively investigate the full etiologic contributors to portal vein thrombosis...
  75. ncbi Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis
    Ozlem Erkan
    Institute of Hepatology, Ankara University, Ankara, Turkey
    Eur J Gastroenterol Hepatol 17:339-43. 2005
    ..Thrombophilic gene mutations have been reported to be associated with the formation of portal vein thrombosis (PVT). This study aimed to investigate the role of thrombophilic gene mutations in cirrhotic patients with PVT...
  76. ncbi Hyperhomocysteinemia and other newly recognized inherited coagulation disorders (factor V Leiden and prothrombin gene mutation) in patients with idiopathic cerebral vein thrombosis
    Paolo Ventura
    Department of Internal Medicine, University of Modena and Reggio Emilia, Italy
    Cerebrovasc Dis 17:153-9. 2004
    ..New, inherited - factor V Leiden (FVL) and prothrombin gene mutation (PTHRA20210) - and inherited/acquired - hyperhomocysteinemia (HHcy) - prothrombotic conditions ..
  77. ncbi Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation
    J M Kemmeren
    Julius Center for General Practice and Patient Oriented Research, University Medical Center Utrecht, The Netherlands
    Thromb Haemost 87:199-205. 2002
    ....
  78. ncbi Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery
    K Wahlander
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg, Sweden
    Thromb Haemost 87:580-5. 2002
    ..countries, scheduled for elective orthopaedic hip or knee surgery, were screened for Factor V Leiden and prothrombin gene G20210A mutations, found in 5.5% and 2.9% of the populations, respectively...
  79. ncbi [Hereditary thrombophilia and systemic sclerosis. An unusual case report]
    Giovanna Minenna
    Sezione di Reumatologia, Dipartimento Medicina Interna e Medicina Pubblica, Universita, Bari
    Recenti Prog Med 98:175-8. 2007
    ..No similar case was reported in literature; therefore, further studies must go ahead understand the possible relation between the two pathologies...
  80. ncbi Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study
    Francis Couturaud
    G E T B O Groupe d Etude de la Thrombose de Bretagne Occidentale, EA 3878, Department of Internal Medicine and Chest Diseases, University Hospital of Brest, Brest, France
    Thromb Haemost 99:223-8. 2008
    ..Sixty-two first-degree relatives of 21 index cases were tested for factor V Leiden, the G20210A prothrombin gene mutation and thrombin generation. Information about oestrogen therapy and previous VTE was also collected...
  81. ncbi Blood coagulation
    S Butenas
    University of Vermont, Department of Biochemistry, Burlington, VT 05405-0068, USA
    Biochemistry (Mosc) 67:3-12. 2002
    ..The characteristic features of the propagation phase are: almost quantitative prothrombin activation at a high rate, completion of platelet activation, and solid clot formation...
  82. ncbi The 2007 John Charnley Award. Factors leading to low prevalence of DVT and pulmonary embolism after THA: analysis of genetic and prothrombotic factors
    Young Hoo Kim
    Joint Replacement Center of Korea, Ewha Womans University School of Medicine, Seoul, Korea
    Clin Orthop Relat Res 465:33-9. 2007
    ..We observed a relationship between DVT and factor V Leiden mutation, antithrombin-III level, and prothrombin promoter G20210A mutation. We saw no relationship between DVT and coagulation or thrombophilic data...
  83. ncbi Beyond unfractionated heparin and warfarin: current and future advances
    Jack Hirsh
    Henderson Research Centre, Hamilton Health Sciences Corporatin, Ontario, Canada
    Circulation 116:552-60. 2007
  84. ncbi Increased thrombin generation in persons with echogenic carotid plaques
    Ann Trude With Notø
    Center for Atherothrombotic Research in Tromsø, Institute of Clinical Medicine, University of Tromsø, Norway
    Thromb Haemost 99:602-8. 2008
    ..Thrombin generation was assessed by thrombin-antithrombin complexes (TAT) and by prothrombin fragment 1+2 (F1+2). Persons with echogenic plaques (n = 63) had significantly higher levels of TAT (5...
  85. ncbi Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy
    Frank Gieseler
    University Hospital of Kiel, Schittenhelmstr 12, 24105 Kiel, Germany
    Thromb Haemost 97:1023-30. 2007
    ..a highly activated coagulation system in blood and their malignant effusions, as indicated by high levels of prothrombin F1.2 fragments and D-dimers...
  86. ncbi Early postoperative obstructive prosthetic mitral valve thrombosis in a patient double heterozygous for factor V Leiden and prothrombin G20210A mutation
    Stefano De Paulis
    Dipartimento di Medicina Cardiovascolare, Policlinico A. Gemelli, Catholic University, Largo Gemelli 8, Rome, Italy
    Thromb Haemost 99:441-2. 2008
  87. ncbi [The influence of hereditary thrombophilic mechanisms on the degree of permanent intravascular coagulation in patients with artificial heart valves]
    T V Vavilova
    Vestn Khir Im I I Grek 163:89-94. 2004
    ..The patients' genotype was estimated by the thrombophylic genes: factor V Leiden (FVL), prothrombin G20210A, methylene tetrahydrofolate reductase C677T, G/A--455FGB, 4G/5G PAI-1, PI A1/A2 GPIIIa...
  88. ncbi Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium
    Ida Martinelli
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, University of Milan, Italy
    Thromb Haemost 87:791-5. 2002
    ..in women with inherited thrombophilia, particularly in carriers of factor V Leiden and of the G20210A prothrombin gene mutation...
  89. ncbi D-dimer as a risk factor for deep vein thrombosis: the Leiden Thrombophilia Study
    Astrid C M Andreescu
    Department of Medicine, University of Vermont, Burlington, USA
    Thromb Haemost 87:47-51. 2002
    ..Excluding participants with Factor V Leiden, prothrombin 20210A, or factors VIIIc or IX above the 90th percentile, the OR was 1.6 (95% CI, 1.1-2.3)...
  90. ncbi The thrombophilias: well-defined risk factors with uncertain therapeutic implications
    K A Bauer
    From Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts, USA
    Ann Intern Med 135:367-73. 2001
    Discovery of the factor V Leiden and prothrombin G20210A mutations has greatly increased the percentage of patients in whom venous thrombosis can be attributed to hereditary thrombophilia...
  91. ncbi Thrombosis: new culprits in an old disorder
    D G Federman
    VA Connecticut Health Care System and Department of Medicine, Yale University School of Medicine, New Haven, CT, USA
    Panminerva Med 44:107-13. 2002
    ..abnormalities associated with thrombophilia include the syndrome of activated Protein C resistance (APCR), the prothrombin 20210A mutation, hyperhomocysteinemia, and elevated levels of coagulation factors VIII and XI...
  92. ncbi Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia
    I Martinelli
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, University of Milan, Italy
    Thromb Haemost 86:800-3. 2001
    ..Also double heterozygous carriers of both the factor V Leiden and the prothrombin gene mutations are at high thrombotic risk...
  93. ncbi Thrombophilia and venous thromboembolism: implications for testing
    Danny M Cohn
    Academic Medical Center, Department of Vascular Medicine, Amsterdam, The Netherlands
    Semin Thromb Hemost 33:573-81. 2007
    ..This article reviews the currently established thrombophilic abnormalities and discusses the potential usefulness and implications of testing for thrombophilia...
  94. ncbi The interaction of fragment 1 of prothrombin with the membrane surface is a prerequisite for optimum expression of factor Va cofactor activity within prothrombinase
    Michael A Bukys
    Cleveland State University, Department of Chemistry, OH 44115, USA
    Thromb Haemost 99:511-22. 2008
    Incorporation of factor (F) Va into prothrombinase directs prothrombin activation by FXa through the meizothrombin pathway, characterized by initial cleavage at Arg(320)...
  95. ncbi The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia
    Elena Rossi
    Institute of Hematology, Catholic University, Rome, Italy
    Thromb Haemost 99:1030-4. 2008
    ..of antithrombin (AT, n = 16), protein C (PC, n = 26), protein S (PS, n = 22), factor V Leiden (FVL, n = 168), prothrombin G20210A (PT-GA, n = 87), or multiple abnormalities (n = 35), and 566 had none of the studied thrombophilic ..
  96. ncbi Primary upper-extremity deep vein thrombosis: high prevalence of thrombophilic defects
    Mariela F Hendler
    Departamento de Hemostasia y Trombosis, Instituto de Investigaciones Hematologicas Mariano R Castex, Academia Nacional de Medicina de Buenos Aires, Buenos Aires, Argentina
    Am J Hematol 76:330-7. 2004
    ..9% anticardiolipin antibodies). Factor V Leiden (12.9%) and prothrombin G20210A mutation (20%) were the most prevalent genetic risk factors. Five patients (16...
  97. ncbi Prothrombin A19911G polymorphism and the risk of venous thromboembolism
    I Martinelli
    Department of Internal Medicine and Medical Specialties, A Bianchi Bonomi Haemophilia and Thrombosis Center, University of Milan, and IRCCS Ospedale Maggiore Policlinico, Mangiagalli and Regina Elena Foundation, Milan, Italy
    J Thromb Haemost 4:2582-6. 2006
    The A > G polymorphism at position 19911 of the prothrombin gene is associated with increased plasma prothrombin levels but its role as a risk factor for venous thromboembolism (VTE) is not established.
  98. ncbi Deep vein thrombosis followed by internal jugular vein thrombosis as a complication of in vitro fertilization in a woman heterozygous for the prothrombin 3' UTR and factor V Leiden mutations
    B M C McGowan
    Haemophilia and Haemostasis Unit, Department of Haematology, Royal Free and University College Medical School, London, England
    Am J Hematol 73:276-8. 2003
    ..We report the case of a 30-year-old woman heterozygous for both the prothrombin 3' UTR mutation and for the factor V Leiden mutation who presented with a proximal deep vein thrombosis ..
  99. ncbi Association of factor V deficiency with factor V HR2
    Elena M Faioni
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and Department of Internal Medicine, University of Milan, Italy
    Haematologica 89:195-200. 2004
    ..018). Double heterozygosity for HR2 and a factor V defect, including factor V deficiency, increased the thrombotic risk afforded by HR2...
  100. ncbi Portal vein thrombosis in children and adolescents: the low prevalence of hereditary thrombophilic disorders
    Raquel B Pinto
    Division of Pediatric Gastroenterology and Hematology Unit, Clinical Pathology Service, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
    J Pediatr Surg 39:1356-61. 2004
    ..The aim of this study was to determine the frequency of thrombophilic disorders in children and adolescents with portal vein thrombosis (PVT) as well as assessing the hereditary character of this disorder...
  101. ncbi Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study
    E R Pomp
    Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
    J Thromb Haemost 6:632-7. 2008
    ..Objective: In the MEGA study, we evaluated pregnancy and the postpartum period as risk factors for venous thrombosis in 285 patients and 857 control subjects...

Research Grants79

  1. Dual Direct Inhibitors of Thrombin and Factor Xa
    Umesh Desai; Fiscal Year: 2009
    ..1) Sulfated DHPs (CDs, FDs and SDs) prolong prothrombin time at concentrations 2-6-fold below that of the clinically used LMWH enoxaparin, while in the activated ..
  2. Dual Direct Inhibitors of Thrombin and Factor Xa
    UMESH RAMANLAL DESAI; Fiscal Year: 2010
    ..1) Sulfated DHPs (CDs, FDs and SDs) prolong prothrombin time at concentrations 2-6-fold below that of the clinically used LMWH enoxaparin, while in the activated ..
  3. Physiology and Molecular Biology of Factor XI
    David Gailani; Fiscal Year: 2009
    ..In Aim 1, we address the hypotheses that fXI is activated by -thrombin in plasma, and that other products of prothrombin activation, such as meizothrombin and -thrombin, activate fXI...
  4. Physiology and Molecular Biology of Factor XI
    David Gailani; Fiscal Year: 2010
    ..In Aim 1, we address the hypotheses that fXI is activated by -thrombin in plasma, and that other products of prothrombin activation, such as meizothrombin and -thrombin, activate fXI...
  5. Improved liver function and regeneration with A20
    Christiane Ferran; Fiscal Year: 2003
    ..Mice expressing A20 maintain normal liver function as assessed by prothrombin time while controls suffer from a severe bleeding diathesis...
  6. Improved liver function and regeneration with A20
    Christiane Ferran; Fiscal Year: 2006
    ..Mice expressing A20 maintain normal liver function as assessed by prothrombin time while controls suffer from a severe bleeding diathesis...
  7. Lipid Regulation of Thrombin Generation
    Barry R Lentz; Fiscal Year: 2010
    Thrombin, the central regulatory molecule of blood coagulation, is produced by prothrombin (II) proteolysis by a platelet-membrane-bound enzyme (factor Xa) and its associated cofactor (factor Va)...
  8. METAL DEPENDENT COMPLEXES IN BLOOD COAGULATION
    Barbara Furie; Fiscal Year: 2002
    ..This application explores the phospholipid binding specificity of prothrombin and the nature of the prothrombin-membrane binding site...
  9. ANTIBODIES WITH PROTHROMBINASE ACTIVITY IN LUPUS
    Perumal Thiagarajan; Fiscal Year: 2003
    b>Prothrombin is the precursor of thrombin, the central enzyme in blood coagulation...
  10. Lipid Regulation of Thrombin Generation
    Barry R Lentz; Fiscal Year: 2010
    Thrombin, the central regulatory molecule of blood coagulation, is produced by prothrombin (II) proteolysis by a platelet-membrane-bound enzyme (factor Xa) and its associated cofactor (factor Va)...
  11. FACTOR VA INTERACTIONS REGULATING PROTHROMBIN ACTIVATION
    Paul Bock; Fiscal Year: 2007
    ..mechanisms of the procoagulant activation of human factor V, factor Va cofactor activity in regulating prothrombin (ProT) activation, and the mechanism of the anticoagulant inactivation of factor Va by activated protein C (ARC)..
  12. FACTOR VA INTERACTIONS REGULATING PROTHROMBIN ACTIVATION
    Paul E Bock; Fiscal Year: 2010
    ..mechanisms of the procoagulant activation of human factor V, factor Va cofactor activity in regulating prothrombin (ProT) activation, and the mechanism of the anticoagulant inactivation of factor Va by activated protein C (ARC)..
  13. FACTOR XI PHYSIOLOGY AND MOLECULAR BIOLOGY
    David Gailani; Fiscal Year: 2004
    ..In contrast to the vitamin K-dependent proteins (prothrombin and factors VII, IX, and X), factor XI lacks a calcium binding Gla domain...
  14. Structure/Function Study of the Anticoagulant Protein S
    Alan Rigby; Fiscal Year: 2005
    ..The penultimate step in blood coagulation is the conversion of prothrombin to thrombin, which is then responsible for the conversion of fibrinogen to fibrin...
  15. MOLECULAR BIOLOGY OF HUMAN COAGULATION FACTOR V
    WILLIAM KANE; Fiscal Year: 1993
    ..In order to understand the mechanisms by which the activation of prothrombin is regulated we have undertaken an investigation of the structure and function of the factor V molecule...
  16. Mechanisms linking the hemostatic protease thrombin to arthritic disease
    Matthew J Flick; Fiscal Year: 2010
    ..Activation of the hemostatic system and the subsequent conversion of prothrombin to the active serine protease thrombin is a prominent feature of RA...
  17. MUTATIONS, HORMONE THERAPY, AND VENOUS THROMBOEMBOLISM
    Bruce Psaty; Fiscal Year: 2001
    ..between hormone replacement therapy and the prothrombotic mutations, Factor V Leiden and the recently described prothrombin mutation (20210A) on the incidence of VTE in a population-based case-control study conducted at Group Health ..
  18. EPIDEMIOLOGY OF HEMOSTASIS IN PERSONS OVER 65
    Russell Tracy; Fiscal Year: 1993
    ..and fibrinolysis in individuals 65 years and older: measures of pro-coagulation (factor antigen VII, prothrombin fragment 1...
  19. Functional Domains of Coagulation Factor V
    Michael Kalafatis; Fiscal Year: 2007
    ..Both chains of the cofactor interact with factor Xa while only the heavy chain of the cofactor binds prothrombin. The factor Va cofactor activity is efficiently down-regulated following proteolysis of the heavy chain by ..
  20. Biomakers in Sickle Cell Anemia: Response to Hydroxyurea
    Marie Stuart; Fiscal Year: 2004
    ..Markers of coagulation activation will include whole blood tissue factor activity (WBTF) and prothrombin fragment F1.2 levels...
  21. PROTEINS OF COAGULATION PATHWAYS
    John Griffin; Fiscal Year: 1999
    ..to C4BP; and iii) similarly, residues on the surface of factor Va are essential for its binding to protein S, prothrombin and factor Xa...